What is Phase Genomics?
Headquartered in Seattle, Phase Genomics specializes in the application of proximity ligation technology to solve complex biological challenges. The company offers a robust portfolio of laboratory kits and computational software designed for diverse applications, including plant, animal, and microbial genomics. By facilitating the deconvolution of metagenomes and the analysis of genome architecture, Phase Genomics serves as a cornerstone for modern biotechnology firms and academic institutions seeking to push the boundaries of genetic research. Their integrated approach—combining wet-lab products with sophisticated analytical software—positions them as a unique provider in the rapidly evolving field of precision medicine and agricultural biotechnology.
How much funding has Phase Genomics raised?
Phase Genomics has raised a total of $7.4M across 4 funding rounds:
Debt
$150K
Debt
$213K
Grant
$5.5M
Other Financing Round
$1.5M
Debt (2020): $150K with participation from PPP
Debt (2021): $213K led by PPP
Grant (2022): $5.5M supported by Bill & Melinda Gates Foundation and National Institute of Allergy and Infectious Diseases
Other Financing Round (2024): $1.5M featuring Bill & Melinda Gates Foundation
Key Investors in Phase Genomics
Bill & Melinda Gates Foundation
Established in 2000 and headquartered in Seattle, Washington, The Bill & Melinda Gates Foundation is an organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives.
National Institute of Allergy and Infectious Diseases
The Vaccine Research Center is an intramural division of the NIAID, part of the NIH, focused on discovering and developing vaccines and antibody-based products to target infectious diseases.
PPP
Public-Private Partnership
What's next for Phase Genomics?
With the infusion of $1.5M, Phase Genomics is well-positioned to scale its operational capacity and expand its suite of genomic analysis tools. The strategic focus will likely center on enhancing the scalability of its metagenomic deconvolution software and broadening the reach of its Hi-C product line into new international markets. As the demand for high-fidelity genomic data grows, the company is expected to leverage its strong institutional backing to accelerate product development cycles and solidify its leadership in the structural genomics space. Future initiatives will likely prioritize the integration of AI-driven computational workflows to further streamline the assembly of complex genomes, ensuring that Phase Genomics remains at the forefront of the genomic revolution.
See full Phase Genomics company page
